Valsartan And Hydrochlorothiazide Tablet, Film Coated
Product Images NDC 71335-2633

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Valsartan And Hydrochlorothiazide (NDC 71335-2633). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

C:\users\ra\desktop\1.jpg (5a5eca60 Figure 01)

A line graph showing the percentage of patients with systolic blood pressure (SBP) less than 140 mmHg plotted against baseline SBP values ranging from 140 to 180 mmHg. The graph compares four groups: Valsartan-HCTZ 320/25 mg (dots), Valsartan 320 mg (triangles), Hydrochlorothiazide 25 mg (squares), and placebo (crosses), illustrating the relative efficacy of each treatment on SBP reduction.*

FDA Label Image

C:\users\ra\desktop\2.jpg (5a5eca60 Figure 02)

A line graph showing the percentage of patients with diastolic blood pressure (DBP) less than 90 mmHg after treatment, plotted against baseline DBP (mmHg). The graph compares four groups: Valsartan-HCTZ 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and Placebo, illustrating the effectiveness of each treatment over the baseline DBP range of 90 to 110 mmHg.*

FDA Label Image

C:\users\ra\desktop\3.jpg (5a5eca60 Figure 03)

A line graph comparing four groups: Valsartan-HCTZ 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and Placebo. The x-axis represents Baseline Systolic Blood Pressure (SBP) in mmHg from 140 to 180, and the y-axis shows the percentage of patients with SBP less than 130 mmHg. The Valsartan-HCTZ combination group shows the highest percentage of patients achieving SBP below 130 mmHg across the baseline range, followed by Valsartan alone, Hydrochlorothiazide alone, and Placebo.*

FDA Label Image

C:\users\ra\desktop\4.jpg (5a5eca60 Figure 04)

A line graph depicting the percentage of subjects with diastolic blood pressure (DBP) below 80 mmHg across varying baseline DBP values (90-110 mmHg). Four groups are compared: Valsartan-HCTZ 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and Placebo, each represented by distinct markers and lines showing treatment effects on DBP.*

FDA Label Image

C:\users\ra\desktop\5.jpg (5a5eca60 Figure 05)

Chemical structure of valsartan, one of the active ingredients in the combination drug valsartan and hydrochlorothiazide. The structure shows characteristic molecular features including aromatic rings and side chains.*

FDA Label Image

C:\users\ra\desktop\6.jpg (5a5eca60 Figure 06)

Chemical structure diagram of the active ingredient shown, illustrating a molecular framework with labeled atoms including nitrogen, sulfur, oxygen, chlorine, and hydrogen in a complex sulfonamide-containing heterocyclic compound.*

FDA Label Image

Label (Lbl713352633)

Label for Valsartan and Hydrochlorothiazide Tablets USP containing 160 mg of valsartan and 25 mg of hydrochlorothiazide per tablet. The film-coated oral tablets are supplied in a package of 30, repackaged by Bryant Ranch Prepack, Inc., and manufactured by Zhejiang Huahai Pharmaceutical Co., Ltd. Includes storage and dispensing instructions along with the NDC 71335-2633-1.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.